Stock MDNA MEDICENNA THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Medicenna Therapeutics Corp.

Equities

MDNA

CA58490H1073

Market Closed - Toronto S.E.
Other stock markets
 03:59:50 2024-06-07 pm EDT 		5-day change 1st Jan Change
2.43 CAD +2.53% Intraday chart for Medicenna Therapeutics Corp. -14.74% +478.57%
Jun. 03 Medicenna Reports "Significant" Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp MT
Jun. 03 Medicenna Brief: Reporting "Significant" Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a "Matched External Control Arm" MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting
AQ
Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum
AQ
Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum
AQ
Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
AQ
Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
GL
Canadian Investment Regulatory Organization Trade Resumption - MDNA
AQ
Canadian Investment Regulatory Organization Trading Halt - MDNA
AQ
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management
GL
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
AQ
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study
AQ
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research
AQ
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
AQ
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
AQ
Medicenna to Present at the 2024 Bloom Burton and Co. Healthcare Investor Conference
AQ
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
AQ
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
AQ
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
AQ
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA in Patients with Advanced Solid Tumors
AQ
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
AQ
Medicenna Announces Appointment of New Auditor
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MDNA Stock
  4. News Medicenna Therapeutics Corp.
  5. Press Releases